Current clinical trials in amyotrophic lateral sclerosis

Bibliography

• CHARCOT J-M: Amyotrophies spinales deuteropathiques sclerose laterale amyotrophique. In: Oeuvrews Completes (Volume 2). Paris: Bureaux du Progres Medical (1874):234-248.
   Google Scholar
• LOWE J, LENNOX G, LEIGH P: Disorders of movements and systems degenerations. In: Greenfield's Neuropathology (6th Edn). Graham DI, Lantos GD (Eds), Arnold, London, UK (1997):281-366.
   Google Scholar
• MCGUIRE V, NELSON LM: Epidemiology of ALS. In: Amyotrophic Lateral Sclerosis. Mitsumoto H, Chad DA, Pioro EP (Eds), Taylor and Francis, New York, NY, USA (2006):17-42.
   Google Scholar
• SIDDIQUE TS, FIGELWICZ DA, PERICAK-VANCE MA et al.: Linkage of a gene causing familial amyotrophic lateral sclerosis to chromosome 21 and evidence of genetic locus heterogeneity. N. Engl. J. Med. (1991) 324:1381-1384.
   PubMed Web of Science ®Google Scholar
• GORDON PH: Advances in clinical trials for amyotrophic lateral sclerosis. Curr. Neurol. Neurosci. Reports (2005) 5:48-54.
   PubMedGoogle Scholar
• BENSIMON G, LACOMBLEZ L, MEININGER V: A controlled trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. (1994) 330:585-591.
   PubMed Web of Science ®Google Scholar
• PRATT J, RATAUD J, BARDOT F et al.: Neuroprotective actions of riluzole in rodent models of global and focal cerebral ischemia. Neurosci. Lett. (1992) 140:225-230.
   PubMed Web of Science ®Google Scholar
• BOIREAU AM, DUBEDAT P, BORDIER F et al.: Riluzole and experimental Parkinsonism: antagonism of MPTP-induced decrease in central dopamine levels in mice. Neuroreport (1994) 5:2657-2660.
   PubMed Web of Science ®Google Scholar
• MILLER RG, MITCHELL JD, LYON M et al.: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst. Rev. (2006) 4:1-10.
   Google Scholar
• LACOMBLEZ L, BENSIMON G, LEIGH PN et al.: Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet (1996) 347:1425-1431.
   Google Scholar
• PAILLISSE C, LACOMBLEZ L, DIB M et al.: Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph. Lat. Scler. (2005) 6:37-44.
   Google Scholar
• BROOKS T, THIRSTED RA, APPEL SH et al.: Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology (2004) 63:1364-1370.
   PubMed Web of Science ®Google Scholar
• ELLIS Y, DAVIES JA: The effects of sigma ligands on the release of glutamate from rat striatal slices. Naunyn-Schmiedebergs Arch. Pharmacol. (1994) 350:143-148.
   PubMed Web of Science ®Google Scholar
• STEINMILLER CL, MAISONNEUVE IM, GLICK SD: Effects of dextromethorphan on dopamine release in the nucleus accumbens: interactions with morphine. Pharmacol. Biochem. Behav. (2003) 74:803-810.
   PubMed Web of Science ®Google Scholar
• TORTELLA FC, PELLICANO M, BOWERY NG: Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol. Sci. (1989) 10:501-507.
   PubMed Web of Science ®Google Scholar
• MAURICE T, URANI A, PHAN VL et al.: The interaction between neuroactive steroids and the sigma 1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res. Rev. (2001) 37:116-132.
   PubMed Web of Science ®Google Scholar
• MILLER RG, MUNSAT TL, SWASH M et al.: Consensus guidelines for the design and implementation of clinical trials in ALS. Subcomittee on Motor Neuron Diseases of the World Federation in Neurology Research Group on Neuromuscular Diseases, 2nd Arlie House Workshop, USA (1998).
   Google Scholar
• MILLER RG, MOORE DH, GELINAS DF et al.: Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology (2001) 56:843-848.
   PubMed Web of Science ®Google Scholar
• CUDKOWICZ ME, SHFNER JM, SHOENFELD DA et al.: Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. (2006) 60:22-31.
   PubMed Web of Science ®Google Scholar
• KAUFMANN P, LEVY G, THOMPSON JP et al.: The ALSFRSr predicts survival time in an ALS clinic population. Neurology (2005) 64:38-43.
   PubMed Web of Science ®Google Scholar
• GROENEVELD GJ, VELDINK JH, VAN DER TWEEL I et al.: A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. (2003) 53:437-445.
   PubMed Web of Science ®Google Scholar
• CHEUNG YK, GORDON PH, LEVIN B: Selecting promising ALS therapies in clinical trials. Neurology (2006) 67:1748-1751.
   PubMed Web of Science ®Google Scholar
• LEVY G, KAUFMANN P, BUCHSBAUM R et al.: A two-stage design for a Phase II clinical trial of coenzyme Q10 in ALS. Neurology (2006) 66:660-663.
   PubMed Web of Science ®Google Scholar
• VAN DEN BOSCH L, TILKIN P, LEMMENS G et al.: Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport (2002) 13:1067-1070.
   PubMed Web of Science ®Google Scholar
• ZHU S, STRAVROVSKAYA IG, DROZDA M et al.: Minocycline inhibits cytochrome C release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 417:74-78.
   PubMed Web of Science ®Google Scholar
• CHEN M, ONA VO, LI M et al.: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat. Med. (2000) 6:797-801.
   PubMed Web of Science ®Google Scholar
• KRIZ J, NGUYEN MD, JULIEN JP et al.: Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. (2002) 10:268-278.
   PubMed Web of Science ®Google Scholar
• GORDON PH, MOORE DH, GELINAS DF et al.: Placebo controlled Phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology (2004) 62:1845-1847.
   PubMed Web of Science ®Google Scholar
• LOWE WL: Insulin like growth factors. Sci. Am. Sci. Med. (1996):62-71.
   Google Scholar
• NEFF NT, PREVETTE D, HOUENOU LJ et al.: Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J. Neurobiol. (1993) 24:1558-1566.
   Google Scholar
• CARONI P, GRANDES P: Nerve sprouting in innervated adult skeletal muscle induced by exposure to elevated levels of insulin-like growth factor. Cell Biol. (1990) 110:1307-1317.
   PubMed Web of Science ®Google Scholar
• LAI, EC, FELICE KJ, FESTOFF FW et al.: Effect of recombinant human insulin-like growth factor I on progression of ALS. Neurology (1997) 49:1621-1630.
   PubMed Web of Science ®Google Scholar
• BORASIO GD, ROBBERECHT W, LEIGH PN et al.: A placebo controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. Neurology (1998) 51:583-586.
   PubMed Web of Science ®Google Scholar
• ROTHSTEIN JD, PATEL S, REGAN MR et al.: β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature (2005) 433:73-77.
   PubMed Web of Science ®Google Scholar
• ROTHSTEIN JD, JIN L, DYKES-HOBERG et al.: Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl. Acad. Sci. USA (1993) 90:6591-6595.
   PubMed Web of Science ®Google Scholar
• DO TQ, SCHULTZ JR, CLARKE CF et al.: Enhanced sensitivity of ubiquinone-deficient mutants of Saccharomyces cerevisiae to products of autooxidized polyunsaturated fatty acids. Proc. Natl. Acad. Sci. USA (1996) 93:7534-7539.
   Google Scholar
• BEAL M: Mitochondria and the pathogenesis of ALS. Brain (2000) 123:1291-1292.
   PubMed Web of Science ®Google Scholar
• SHULTS CW, OAKES D, KIEBURTZ K et al.: Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. (2002) 59:1541-1550.
   PubMed Web of Science ®Google Scholar
• FERRANTE, KL, SHEFNER J, ZHANG H et al.: Tolerance of high dose (3000 mg/day) coenzyme Q10 in ALS. Neurology (2005) 65:1834-1836.
   PubMed Web of Science ®Google Scholar
• KAWAMATA T, AKIYAMA H, YAMADA T et al.: Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. (1992) 140:691-707.
   PubMed Web of Science ®Google Scholar
• VIEIRA PL, HEYSTEK HC, WORMMEESTER J et al.: Glatiramer acetate promotes TH2 development and increased IL-10 production through modulation of dendritic cells. J. Immunol. (2003) 170:4483-4488.
   PubMed Web of Science ®Google Scholar
• ANGELOV DN, WAIBEL S, GUNTINAS-LICHIUS O et al.: Therapeutic vaccine for acute and chronic motor neuron disease: implications for amyotrophic lateral sclerosis. Proc. Nat. Acad. Sci. USA (2003) 100:4790-4795.
   PubMed Web of Science ®Google Scholar
• BENNER EJ, MOSLEY RL, DESTACHE CJ et al.: Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease. Proc. Natl. Acad. Sci. USA (2004) 101:9435-9440.
   PubMed Web of Science ®Google Scholar
• GORDON PH, DOORISH C, MONTES J et al.: Randomized controlled Phase II trial of glatiramer acetate in ALS. Neurology (2006) 66:1117-1119.
   PubMed Web of Science ®Google Scholar
• LANIUS RA, PADDON HB, MEZEI M et al.: A role for amplified protein kinase C activity in the pathogenesis of amyotrophic lateral sclerosis. J. Neurochem. (1995) 65:927-930.
   PubMed Web of Science ®Google Scholar
• WAGEY R, PELECH SL, DURONIO V et al.: Phosphatidylinositol 3-kinase: increased activity and protein level in amyotrophic lateral sclerosis. J. Neurochem. (1998) 71:716-722.
   PubMed Web of Science ®Google Scholar
• HU JH, ZHANG H, WAGEY R et al.: Protein kinase and protein phosphatase expression in amyotrophic lateral sclerosis spinal cord. J. Neurochem. (2003) 85:432-442.
   PubMed Web of Science ®Google Scholar
• BATTANI F: Protein kinase C isoforms as therapeutic targets in nervous system disease states. Pharmacol. Res. (2001) 44:353-361.
   PubMed Web of Science ®Google Scholar
• CORDEY M, GUNDIMEDA U, GOPALKRISHNA R et al.: Estrogen activates protein kinase C in neurons: role in neuroprotection. J. Neurochem. (2003) 84:1340-1348.
   PubMed Web of Science ®Google Scholar
• BROOKS B, SANJAK M, ROELKE K et al.: Phase IIB randomized dose ranging clinical trial of tamoxifen, a selective estrogen receptor modulator [SERM], in ALS: sensitivity analyses of discordance between survival and functional outcomes with long term follow-up. Amyotroph. Lat. Scler. (2005) 6(Suppl. 1):118.
   Web of Science ®Google Scholar
• TAKAYAMA S, REED JC, HOMMA S: Heat shock proteins as regulators of apoptosis. Oncogene (2003) 22(56):9041-9047.
   PubMed Web of Science ®Google Scholar
• CLEVELAND DW: From charcot to SOD1: mechanisms of selective motor neuron death in ALS. Neuron (1999) 24:515-520.
   PubMed Web of Science ®Google Scholar
• VLEMINCKX V, VAN DAMME P, GOFFIN K et al.: Upregulation of HSP27 in a transgenic model of ALS. J. Neuropath. Exp. Neurol. (2002) 61:968-974.
   PubMed Web of Science ®Google Scholar
• HARGITAI J, LEWIS H, BOROS I et al.: Bimoclomol, a heat shock protein co-inducer, acts by the prolonged activation of heat shock factor-1. Biochem. Biophys. Res. Commun. (2003) 307:689-695.
   PubMed Web of Science ®Google Scholar
• KIERAN D, KALMAR B, DICK JR et al.: Treatment with arimoclomol, a heat shock inducer protein, delays disease progression in ALS mice. Nat. Med. (2004) 10:402-405.
   PubMed Web of Science ®Google Scholar
• SHAW PJ, FORREST V, INCE PG et al.: CSF and plasma amino acid levels in motor neuron disease-elevation of CSF glutamate in a subset of patients. Neurodegeneration (2005) 4:209-216.
   Google Scholar
• ROTHSTEIN JD, DYKES-HOBERG M, PARDO CA et al.: Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron (1996) 16:675-686.
   PubMed Web of Science ®Google Scholar
• VAN DAMME P, LEYSSEN M, CALLEWAERT G et al.: The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci. Lett. (2003) 343:81-84.
   PubMed Web of Science ®Google Scholar
• LANGAN YM, LUCAS R, JEWELL H et al.: Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia (2003) 1:46-53.
   Google Scholar
• JEWELL H, LUCAS R, SCHAEFER H et al.: LY300164 initial expression in healthy subjects. Clin. Pharacol. Ther. (1998) 63:188.
   Google Scholar
• TRAYNOR B, BRUIJN L, CONWIT R et al.: Neuroprotective agents in clinical trials in ALS. Neuroloy (2006) 67:20-27.
   PubMed Web of Science ®Google Scholar
• KLIVENYI P, FERRANTE RJ, MATTHEWS RT et al.: Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. (1999) 5:347-350.
   PubMed Web of Science ®Google Scholar
• DRACHMAN DB, KRYSTL F, DYKES-HOBERG M et al.: Cyclooxygenase-2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. (2002) 52:771-778.
   PubMed Web of Science ®Google Scholar
• KLIVENYI P, KIAEI M, GARDIAN G et al.: Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem. (2004) 88:576-582.
   PubMed Web of Science ®Google Scholar
• ZHANG W, NARAYANAN M, FRIEDLANDER RM: Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. (2003) 2:267-270.
   Google Scholar
• BOWLER RP, SHENG H, ENGHILD JJ et al.: A catalytic antioxidant (AEOL 10150) attenuates expression of inflammatory genes in stroke. Free Radic. Biol. Med. (2002) 33:1141-1152.
   PubMed Web of Science ®Google Scholar
• FERRER-SUETA G, VITTURI D, BATINIC-HABERLE I et al.: Reactions of manganese porphyrins with peroxynitrite and carbonate radical anion. J. Biol. Chem. (2003) 78:27432-27438.
   Google Scholar
• ESTEVEZ AG, CROW JP, SAMPSON JB et al.: Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science (1999) 286:2498-2500.
   PubMed Web of Science ®Google Scholar
• ESTEVEZ AG, SPEAR M, MANUEL SM et al.: Nitric oxide and superoxide contribute to motor neuron apoptosis induced by trophic factor deprivation. J. Neurosci. (1998) 18:923-931.
   PubMed Web of Science ®Google Scholar
• CHA CI, CHUNG YH, SHIN CM et al.: Immunocytochemical study on the distribution of nitrotyrosine in the brain of the transgenic mice expressing a human Cu/Zn SOD mutation. Brain Res. (2000) 853:156-161.
   PubMed Web of Science ®Google Scholar
• CROW JP, CALINGASAN NY, CHEN JP et al.: Manganese pophyrin given at symptom onset markedly extends survival of ALS mice. Ann. Neurol. (2005) 58:258-265.
   PubMed Web of Science ®Google Scholar
• GORE SD, CARDUCCI MA: Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors. Expert Opin. Investig. Drugs (2000) 9:2923-2934.
   PubMed Web of Science ®Google Scholar
• YOSHIHARA T, ISHIGAKI S, YAMAMOTO M et al.: Differential expression of inflammation-and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. (2002) 80:158-167.
   PubMed Web of Science ®Google Scholar
• ISHIGAKI S, NIWA J, ANDO Y et al.: Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett. (2002) 531:354-358.
   PubMed Web of Science ®Google Scholar
• GONZALEZ DE AGUILAR JL, GORDON JW, RENE F et al.: Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway. Neurobiol. Dis. (2000) 7:406-415.
   Google Scholar
• RYU H, SMITH K, CAMELO S et al.: Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. (2005) 93:1087-1098.
   PubMed Web of Science ®Google Scholar
• WESSELS DH, GROVER R, FREND A et al.: A randomised, double blind, placebo controlled single ascending dose study of PYM50018, with an open label cross-over stage to assess food effect. Clin. Pharmacol. Ther. (2005) 77:67.
   Google Scholar
• ABITBOL JL, CUVIER V, BORDET T et al.: Safety and pharmacokinetics of repeated doses of TRO19622, a drug candidate for the treatment of amyotrophic lateral sclerosis and spinal muscular atrophy. Amyotroph. Lat. Scler. (2006) 7(Suppl. 1):112-113.
   PubMed Web of Science ®Google Scholar
• GORDON PH: Clinical trial methodology. In: Amyotrophic Lateral Sclerosis. Mitsumoto H, Chad DA, Pioro EP (Eds), Taylor and Francis, New York, NY, USA (2006):583-599.
   Google Scholar
• SMITH RA, MILLER TM, YAMANAKA K et al.: Antisense oligonucleotide therapy for neurodegenerative disease. J. Clin. Invest. (2006) 116:2290-2296.
   PubMed Web of Science ®Google Scholar
• CORCORAN LJ, MITCHINSON TJ, LIU Q et al.: A novel action of histone deacetylase inhibitors in a protein aggresome disease model. Curr. Biol. (2004) 14:488-492.
   PubMed Web of Science ®Google Scholar
• CLEMENT AM, NGUYEN MD, ROBERTS EA et al.: Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science (2003) 302:113-117.
   Google Scholar
• SILANI V, CAVA L, CORBO M et al.: Stem cell therapy for amyotrophic lateral sclerosis. Lancet (2004) 364:200-202.
   PubMed Web of Science ®Google Scholar
• JANSON CG, RAMESH TM, DURING MJ et al.: Human intrathecal transplantation of peripheral blood stem cells in amyotrophic lateral sclerosis. J. Hematother. Stem Cell Res. (2001) 10:913-915.
   PubMedGoogle Scholar
• KASPAR B, LLADO J, SHERKAT N et al.: Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science (2003) 301:839-842.
   PubMed Web of Science ®Google Scholar
• AZZOUZ M, RALPH GS, STORKEBAUM E et al.: VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature (2004) 429:413-417.
   PubMed Web of Science ®Google Scholar
• SCHYMICK JC, SCHOLZ SW, FUNG HC et al.: Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. (2007) 4:322-328.
   Google Scholar
• DYKXHOORN DM, NOVINA CD, SHARP PA et al.: Killing the messenger: short RNA's that silence gene expression. Nat. Rev. Mol. Cell Biol. (2003) 4:457-467.
   PubMed Web of Science ®Google Scholar
• ABBAS-TERKI T, BLANCO-BOSE W, DEGLON N et al.: Lentiviral mediated RNA interference. Hum. Gene Ther. (2002) 13:2197-2201.
   Google Scholar
• RAOUL C, ABBAS-TERKI T, BENSADOUN JC et al.: Lentiviral-mediated silencing of SOD1 through RNA interferences retards disease onset and progression in mouse model of ALS. Nat. Med. (2005) 11:423-428.
   PubMed Web of Science ®Google Scholar
• MILLER T, KASPAR BK, KOPS GJ et al.: Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis. Ann. Neurol. (2005) 57:773-776.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-LEBRON E, PAULSON HL: Allele-specific RNA interference for neurological disease. Gene Ther. (2006) 13:576-581.
   PubMed Web of Science ®Google Scholar